PHILLIP BOWMAN: Open Payments
NPI 1619231701 · SALT LAKE CITY, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,473 in 162 payments from 18 companies in 2025. Trend: 2023 $2,564 · 2024 $2,883 · 2025 $2,473
Food & beverage: $2,473
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 46 | $616 |
| Ardelyx, Inc. | 15 | $249 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $238 |
| PFIZER INC. | 27 | $216 |
| Janssen Biotech, Inc. | 15 | $216 |
| Aimmune Therapeutics, Inc. | 12 | $188 |
| Gilead Sciences, Inc. | 8 | $183 |
| Madrigal Pharmaceuticals | 4 | $111 |
| Regeneron Healthcare Solutions, Inc. | 5 | $95 |
| GENZYME CORPORATION | 5 | $94 |
Products named: IBSRELA, RINVOQ, ENTYVIO, TREMFYA, DUPIXENT, ZENPEP, XELJANZ, SKYRIZI.
Industry payments across UT — which companies pay providers there.
